Related references
Note: Only part of the references are listed.Does salmon calcitonin cause cancer? A review and meta-analysis
G. Wells et al.
OSTEOPOROSIS INTERNATIONAL (2016)
The environment and disease: association or causation? (Reprinted from JRSM, vol 58, 1965)
Austin Bradford Hill
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2015)
Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials
M. A. Karsdal et al.
OSTEOARTHRITIS AND CARTILAGE (2015)
Additive effect of elcatonin to risedronate for chronic back pain and quality of life in postmenopausal women with osteoporosis: a randomized controlled trial
Michio Hongo et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2015)
New insights into treatment of osteoporosis in postmenopausal women
Piet Geusens
RMD OPEN (2015)
Emerging Therapies for Osteoporosis
Michael R. McClung
ENDOCRINOLOGY AND METABOLISM (2015)
Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats
Michael Feigh et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Osteoporosis Medication Use After Hip Fracture in U.S. Patients Between 2002 and 2011
Daniel H. Solomon et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Calcitonin Nasal Spray and Increased Cancer Risk: A Population-Based Nested Case-Control Study
Li-Min Sun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Prevention and treatment of postmenopausal osteoporosis
Sri Harsha Tella et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2014)
Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial
N. Binkley et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Formulation strategies to improve oral peptide delivery
Sam Maher et al.
PHARMACEUTICAL PATENT ANALYST (2014)
Salmon Calcitonin Use and Associated Cancer Risk
Robert A. Overman et al.
ANNALS OF PHARMACOTHERAPY (2013)
Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012
Diane K. Wysowski et al.
BONE (2013)
Oral salmon calcitonin protects against impaired fasting glycemia, glucose intolerance, and obesity induced by high-fat diet and ovariectomy in rats
Michael Feigh et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2013)
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2013)
A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis
Luisella Cianferotti et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2013)
Elcatonin in Combination with Risedronate Is More Effective than Risedronate Alone for Relieving Back Pain in Postmenopausal Women with Osteoporosis
Masayuki Takakuwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2012)
Oral Salmon Calcitonin Improves Fasting and Postprandial Glycemic Control in Lean Healthy Rats
M. Feigh et al.
HORMONE AND METABOLIC RESEARCH (2012)
A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial
Neil Binkley et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis
J. A. Knopp-Sihota et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Oral Calcitonin
Michael J. Maricic
CURRENT OSTEOPOROSIS REPORTS (2012)
Oral calcitonin
Ronald C. Hamdy et al.
INTERNATIONAL JOURNAL OF WOMENS HEALTH (2012)
Peptide therapeutics: it's all in the delivery
Marshall Grant et al.
THERAPEUTIC DELIVERY (2012)
A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats
M. Feigh et al.
DIABETES OBESITY & METABOLISM (2011)
Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
M. A. Karsdal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacy
Morten A. Karsdal et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study
M. A. Karsdal et al.
OSTEOARTHRITIS AND CARTILAGE (2010)
A Pharmacokinetic and Pharmacodynamic Comparison of Synthetic and Recombinant Oral Salmon Calcitonin
Morten A. Karsdal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Nasal Delivery of High Molecular Weight Drugs
Yildiz Ozsoy et al.
MOLECULES (2009)
Salmon calcitonin: a review of current and future therapeutic indications
C. H. Chesnut et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis
Daniel-Henri Manicourt et al.
ARTHRITIS AND RHEUMATISM (2006)
Thyroid cancer and multiple primary tumors in the SEER cancer registries
CM Ronckers et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women:: A new potential treatment of osteoarthritis
YZ Bagger et al.
BONE (2005)
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results from the QUEST study
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women:: Acute and 3-month effects on biomarkers of bone turnover
LB Tankó et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers
T Buclin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (Serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting
P Qvist et al.
BONE (2002)
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study
CH Chesnut et al.
AMERICAN JOURNAL OF MEDICINE (2000)
Share Paper
